Download
00392_2023_Article_2181.pdf 1,44MB
WeightNameValue
1000 Titel
  • Comparison of a novel self-expanding transcatheter heart valve with two established devices for treatment of degenerated surgical aortic bioprostheses
1000 Autor/in
  1. Nikolayevska, Olga |
  2. Conradi, Lenard |
  3. Schirmer, Johannes |
  4. Reichenspurner, Hermann |
  5. Deuschl, Florian |
  6. Blankenberg, Stefan |
  7. Schäfer, Ulrich |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-04-05
1000 Erschienen in
1000 Quellenangabe
  • 113(1):18-28
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00392-023-02181-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10808493/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Aims</jats:title> <jats:p>This study was performed to compare haemodynamic properties of a novel transcatheter heart valve (THV) with two established valve technologies for treatment of failing surgical aortic bioprosthetic valves (SAV). The ALLEGRA THV has been recently described with a proven safety and performance profile.</jats:p> </jats:sec><jats:sec> <jats:title>Methods and results</jats:title> <jats:p>The study was designed as a retrospective, single-centre study investigating 112 patients (77.7 ± 7.1 years, 53.8% female, STS score 6.8 ± 5.8% and logEuroSCORE I 27.4 ± 16.1%) with failing SAV. Patients were treated with the ALLEGRA THV (NVT, n = 24), the CoreValve/EvolutR (MTD, n = 64) or the Edwards Sapien/Sapien XT/Sapien 3 (EDW, n = 24). Adverse events, haemodynamic outcomes and patient safety were analysed according to VARC-3 definitions. Overall procedural success was high (94.6%), even though 58.9% of the treated SAV were classified as small (true inner diameter &lt; 21 mm). After treatment, the mean pressure gradient was significantly reduced (baseline: 33.7 ± 16.5 mmHg, discharge: 18.0 ± 7.1 mmHg), with a corresponding increase in effective orifice area (EOA). The complication rates did not differ in between groups. There was a trend to lower mean transvalvular gradients after implantation of self-expanding THV with supra-annular valve function, despite a higher frequency of smaller SAVs in the NVT and MTD group. Additionally, comparison between NVT and MTD revealed statistically lower transvalvular gradients (NVT 14.9 ± 5.0 mmHg, MTD 18.7 ± 7.5 mmHg, <jats:italic>p</jats:italic> = <jats:italic>0.0295</jats:italic>) in a subgroup analysis.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Valve-in-valve (ViV) treatment of failing SAV with supra-annular design like the ALLEGRA THV resulted in favourable haemodynamic outcomes with similar low clinical event rates and may therefore be an interesting alternative for VIV TAVI.</jats:p> </jats:sec><jats:sec> <jats:title>Graphical abstract</jats:title> </jats:sec>
1000 Sacherschließung
lokal Female [MeSH]
lokal Bioprosthetic valves
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Aortic Valve/surgery [MeSH]
lokal Retrospective Studies [MeSH]
lokal Heart Valve Prosthesis [MeSH]
lokal Male [MeSH]
lokal Transcatheter Aortic Valve Replacement/methods [MeSH]
lokal Aortic valve disease
lokal Original Paper
lokal TAVI
lokal Aortic Valve Stenosis/surgery [MeSH]
lokal Bioprosthesis [MeSH]
lokal Valve-in-valve
lokal Prosthesis Design [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-2784-0205|https://frl.publisso.de/adhoc/uri/Q29ucmFkaSwgTGVuYXJk|https://frl.publisso.de/adhoc/uri/U2NoaXJtZXIsIEpvaGFubmVz|https://frl.publisso.de/adhoc/uri/UmVpY2hlbnNwdXJuZXIsIEhlcm1hbm4=|https://frl.publisso.de/adhoc/uri/RGV1c2NobCwgRmxvcmlhbg==|https://frl.publisso.de/adhoc/uri/QmxhbmtlbmJlcmcsIFN0ZWZhbg==|https://frl.publisso.de/adhoc/uri/U2Now6RmZXIsIFVscmljaA==
1000 Hinweis
  • DeepGreen-ID: c406d5cad04a4778ad1b04a4da89a22c ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Hamburg-Eppendorf (UKE) |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Hamburg-Eppendorf (UKE) |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6521935.rdf
1000 Erstellt am 2025-07-06T11:23:07.877+0200
1000 Erstellt von 322
1000 beschreibt frl:6521935
1000 Zuletzt bearbeitet 2025-07-31T15:03:33.584+0200
1000 Objekt bearb. Thu Jul 31 15:03:33 CEST 2025
1000 Vgl. frl:6521935
1000 Oai Id
  1. oai:frl.publisso.de:frl:6521935 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source